Clinical trial

PAlbociclib and Circulating Tumor DNA for ESR1 Mutation Detection

NCT03079011

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2017-03-22

PhasePHASE3

Study timeline

Study start (actual)2017-03-22Date precision: day

Registry last updated2025-11-18

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Metastatic Breast Cancerunresolved

Interventions

Palbociclib 125mgDRUG

Aromatase InhibitorsDRUG

Fulvestrant Injectable ProductDRUG

Sponsors & collaborators

UNICANCERlead sponsor

Pfizercollaborator

Mapped research locations

ParisFrance4 StrasbourgFrance4 MarseilleFrance3 LyonFrance3 BordeauxFrance3 ToulouseFrance2 Clermont-FerrandFrance2 BrestFrance2 LimogesFrance2 MontpellierFrance1 NantesFrance1 RennesFrance1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT03079011 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.